TICKERNERD
Menu
OVIDOVIDHealthcare · Biotechnology

OVID Stock Forecast: Ovid Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$2.81
+0.36% on the day

The 10 Wall Street analysts covering Ovid Therapeutics, Inc. hold a median 12-month price target of $5 — +77.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$546.8M
Ticker Nerd rank
68 / 100
Median analyst target
$5.00
Analysts covering
10
Revenue$0.0−100.0% y/y
Operating income−$17.8M
Net income−$17.0M
Free cash flow−$13.9M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.8%
1M
+20.6%
YTD
+72.4%
1Y
+172.8%
From 52W high
−5.1%
From 52W low
+146.5%
$1.14
$2.96
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OVID stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ovid Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
68 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
99
Revisions
89
Quality
76
Size
53
Value
48
Growth
47
Issuance
37
Volatility
30
Accruals
18

Momentum (99): The shares have been drifting up relative to others.

Accruals (18): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OVID stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OVID, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26OVIDHigh $9.00Median $5.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
10 Buy0 Hold0 Sell
Low $4.00Median $5.00High $9.00

The green dot is the last close — the median target sits +77.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Aug 2026OppenheimerMaintainsOutperform$7.00 → $9.00
15 Apr 2026WedbushReiteratesOutperform—
15 Apr 2026WedbushReiteratesOutperform$7.00
9 Apr 2026HC Wainwright & Co.MaintainsBuy—
9 Apr 2026HC Wainwright & Co.MaintainsBuy$2.00 → $4.00
26 Mar 2026BTIGReiteratesBuy—
20 Mar 2026WedbushMaintainsOutperform—
22 Dec 2025HC Wainwright & Co.ReiteratesBuy—
22 Dec 2025LifeSci CapitalInitiatesOutperform—
11 Dec 2025Roth CapitalInitiatesBuy—
24 Nov 2025HC Wainwright & Co.MaintainsBuy—
17 Nov 2025Leerink PartnersInitiatesOutperform—
27 May 2025HC Wainwright & Co.MaintainsBuy—
24 Mar 2025BTIGMaintainsBuy—
24 Mar 2025HC Wainwright & Co.MaintainsBuy—
12 Mar 2025WedbushMaintainsOutperform—
29 Jan 2025OppenheimerUpgradeOutperform—
4 Dec 2024HC Wainwright & Co.ReiteratesBuy—
30 Sept 2024HC Wainwright & Co.ReiteratesBuy—
19 Aug 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OVID appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

OVID vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Ovid Therapeutics, Inc. returned +172.8% against +19.6% for the S&P 500, dividends included.

OVID vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Oct 25Jan 26Apr 26Jul 26OVIDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OVID analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
5
Fundamentals

Ovid Therapeutics, Inc. (OVID) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.8×

Cheaper than 94% of US stocks

Price / sales
333.7×

Cheaper than 2% of US stocks

Price / book
2.4×

Cheaper than 41% of US stocks

EV / EBITDA
−7.6×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
−88.3%

Higher than 2% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−2100.7%

Higher than 4% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−26.0%

Higher than 29% of US stocks

Return on assets
−23.5%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Ovid Therapeutics, Inc. (OVID) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Ovid Therapeutics, Inc. has a market value of $546.8M and an enterprise value of $442.3M.

  • Revenue in the twelve months to 31 Mar 2026: $7.1M. The latest quarter shrank 88.3% year on year.

  • Net income over the same four quarters: −$24.2M, a −339.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.29.

  • Free cash flow in the twelve months to 31 Mar 2026: −$42.0M.

  • Shares outstanding: 167.3M.

  • Trailing P/E: −11.8×; forward P/E: −6.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Ovid Therapeutics, Inc. employs 23 people — $310K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

OVID vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OVIDOvid Therapeutics, Inc.$546.8M
68
PRLDPrelude Therapeutics, Inc.$528.0M
96
ARTVArtiva Biotherapeutics, Inc.$531.1M
37
CABACabaletta Bio, Inc.$510.3M
30
KYTXKyverna Therapeutics, Inc.$508.9M
41
PRTAProthena Corp. Plc$508.7M
98
EVMNEvommune, Inc.$505.0M
10

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ovid Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OVID news & analysis

What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?

Zacks Investment Research · 18 Aug 2026positive

Zacks Investment Research published an article examining whether Ovid Therapeutics (OVID) qualifies as a strong momentum stock pick for investors. The piece evaluates the company's characteristics against momentum-investing criteria.

Why it matters — The article highlights Ovid Therapeutics as a potential momentum stock, which could draw investor attention to the company's current market positioning.

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 13 Aug 2026neutral

Ovid Therapeutics reported a quarterly loss of $0.08 per share for Q2, which was narrower than the Zacks Consensus Estimate of a $0.10 loss but wider than the $0.06 loss recorded in the same quarter a year ago. The results came in ahead of revenue estimates.

Why it matters — A Ovid watcher would care because the company's quarterly loss came in better than analyst expectations while also signaling a year-over-year widening in its losses.

Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

GlobeNewsWire · 13 Aug 2026neutral

Ovid Therapeutics provided business updates and reported its financial results for the second quarter ended June 30, 2026, in a company announcement issued on August 13, 2026. The biopharmaceutical company, focused on brain disorder treatments, detailed these updates via press release.

Why it matters — A Ovid watcher would care because the quarterly financial results and business updates offer an official look at the company's recent operational and financial progress.

Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline

Zacks Investment Research · 5 Aug 2026negative

Zacks Investment Research published an earnings preview for Ovid Therapeutics' upcoming Q2 report, noting the company lacks the combination of key ingredients typically associated with a likely earnings beat. The article advises investors to prepare with the key expectations for the report.

Why it matters — OVID watchers would care because the preview signals that the company's upcoming Q2 earnings may fall short of expectations, setting the tone ahead of the report.

FAQ

Frequently asked questions about OVID stock

What is the OVID stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Ovid Therapeutics, Inc. have a median 12-month price target of $5, with estimates ranging from $4 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OVID stock a buy right now?

Of the 10 analysts covering Ovid Therapeutics, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ovid Therapeutics, Inc. 68 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OVID?

As at 22 Aug 2026, Ovid Therapeutics, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

Will OVID stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +77.9% from the last close, and Ticker Nerd's factor model ranks Ovid Therapeutics, Inc. 68 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OVID stock forecast for 2030?

No analyst covering Ovid Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OVID are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $9 over the next 12 months.

How has OVID stock performed over the past year?

Ovid Therapeutics, Inc. returned +172.8% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ovid Therapeutics, Inc. do?

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines for brain conditions characterized by excess neural excitability, such as rare neurological disorders, epilepsies, and seizure-related issues.

What is the latest news on OVID?

The most recent item we track (Zacks Investment Research, 18 Aug 2026): "What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?". Zacks Investment Research published an article examining whether Ovid Therapeutics (OVID) qualifies as a strong momentum stock pick for investors. The piece evaluates the company's characteristics against momentum-investing criteria.

Company

About Ovid Therapeutics, Inc.

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines for brain conditions characterized by excess neural excitability, such as rare neurological disorders, epilepsies, and seizure-related issues. The company advances a pipeline targeting neuronal hyperexcitability to restore excitatory-inhibitory balance in the brain. Key programs include OV329, a next-generation GABA-aminotransferase inhibitor designed to increase GABA levels for treatment-resistant seizures with potentially improved safety over prior drugs, currently in Phase 1 clinical trials. Ovid Therapeutics also develops a portfolio of KCC2 direct activators, including OV350 as an intravenous tool compound evaluated in Phase 1 for foundational safety data, and OV4071, an oral candidate prioritized for neuropsychiatric conditions like psychosis in Parkinson's disease and Lewy body dementia. Additional compounds from its proprietary KCC2 library support oral and injectable formulations for neurological, neurodevelopmental, and neurodegenerative applications. Founded in 2014 and headquartered in New York, Ovid Therapeutics concentrates on biomarker-driven development for central nervous system disorders with significant unmet needs.

CEO Ms. Margaret Alexander · 23 employees · United States · https://www.ovidrx.com